髓母细胞瘤
癌症干细胞
干细胞
癌症研究
生物
干细胞标记物
细胞培养
肿瘤科
医学
细胞生物学
遗传学
作者
Arianna Casciati,Mirella Tanori,Rémi Manczak,Sofiane Saada,Barbara Tanno,Paola Giardullo,Elena Porcù,Elena Rampazzo,Luca Persano,Giampietro Viola,Claire Dalmay,Fabrice Lalloué,Arnaud Pothier,Caterina Merla,Mariateresa Mancuso
出处
期刊:Cancers
[MDPI AG]
日期:2020-01-17
卷期号:12 (1): 226-226
被引量:30
标识
DOI:10.3390/cancers12010226
摘要
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Despite the progress of new treatments, the risk of recurrence, morbidity, and death remains significant and the long-term adverse effects in survivors are substantial. The fraction of cancer stem-like cells (CSCs) because of their self-renewal ability and multi-lineage differentiation potential is critical for tumor initiation, growth, and resistance to therapies. For the development of new CSC-targeted therapies, further in-depth studies are needed using enriched and stable MB-CSCs populations. This work, aimed at identifying the amount of CSCs in three available human cell lines (DAOY, D341, and D283), describes different approaches based on the expression of stemness markers. First, we explored potential differences in gene and protein expression patterns of specific stem cell markers. Then, in order to identify and discriminate undifferentiated from differentiated cells, MB cells were characterized using a physical characterization method based on a high-frequency dielectrophoresis approach. Finally, we compared their tumorigenic potential in vivo, through engrafting in nude mice. Concordantly, our findings identified the D283 human cell line as an ideal model of CSCs, providing important evidence on the use of a commercial human MB cell line for the development of new strategic CSC-targeting therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI